US2023212137A1PendingUtilityA1
Solid forms of 2-(4-chlorophenyl)-n-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)-2,2-difluoroacetamide, and their pharmaceutical compositions and uses
Est. expiryJan 8, 2036(~9.5 yrs left)· nominal 20-yr term from priority
Inventors:Paul F. FernandezAntonio Christian FerrettiMohit Atul KothareYing LiHon-Wah ManWeihong Zhang
A61K 9/0014C07D 401/04A61K 9/19C07K 16/00A61K 31/454A61K 45/06A61K 31/513A61K 2039/505A61K 9/08A61K 9/0019A61K 39/395A61P 35/00A61P 35/02A61P 43/00C07B 2200/13
75
PatentIndex Score
0
Cited by
0
References
0
Claims
Abstract
Solid forms comprising 2-(4-chlorophenyl)-N-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)-2,2-difluoroacetamide, compositions comprising the solid forms, methods of making the solid forms and methods of their uses are disclosed.
Claims
exact text as granted — not AI-modifiedWhat is claimed is:
1 . A solid form of 2-(4-chlorophenyl)-N-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)-2,2-difluoroacetamide or a tautomer thereof:
wherein the solid form is selected from: Form D having an X-ray powder diffraction pattern comprising peaks at about 14.1, 14.3, 18.8 or 19.1 degrees 2θ; and Form E having an X-ray powder diffraction pattern comprising peaks at about 16.1, 17.0, 21.2 or 22.9 degrees 2θ.
2 . The solid form of claim 1 , which is anhydrous.
3 . The solid form of claim 1 , which is Form D having an X-ray powder diffraction pattern comprising peaks at about 14.1, 14.3, 18.8 or 19.1 degrees 2θ.
4 . The solid form of claim 3 , having an X-ray powder diffraction pattern comprising peaks at about 14.1, 14.3, 18.8, 19.1, 23.6 or 24.0 degrees 2θ.
5 . The solid form of claim 3 , having an X-ray powder diffraction pattern substantially as shown in FIG. 23 .
6 . The solid form of claim 3 , having a thermal gravimetric analysis plot comprising a mass loss of about 14.1% up to about 140° C.
7 . The solid form of claim 3 , having a thermal gravimetric analysis plot substantially as shown in FIG. 24 .
8 . The solid form of claim 3 which is substantially pure.
9 . The solid form of claim 3 which is a DMSO solvate.
10 . The solid form of claim 1 , which is Form E having an X-ray powder diffraction pattern comprising peaks at about 16.1, 17.0, 21.2 or 22.9 degrees 2θ.
11 . The solid form of claim 10 , having an X-ray powder diffraction pattern comprising peaks at about 10.5, 12.5, 16.1, 17.0, 18.5, 21.2, 21.7, 22.6, 22.9, 23.4, 23.8, 24.1, 25.1 or 26.7 degrees 2θ.
12 . The solid form of claim 10 , having an X-ray powder diffraction pattern substantially as shown in FIG. 25 .
13 . The solid form of claim 10 , having a thermal gravimetric analysis plot comprising a mass loss of about 19.4% up to about 120° C.
14 . The solid form of claim 10 , having a thermal gravimetric analysis plot substantially as shown in FIG. 26 .
15 . The solid form of claim 10 which is substantially pure.
16 . The solid form of claim 10 which is a DMSO solvate.
17 . An amorphous form of 2-(4-chlorophenyl)-N-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)-2,2-difluoroacetamide or a tautomer thereof:
.
18 . The amorphous form of claim 17 having a differential scanning calorimetry plot substantially as shown in FIG. 27 .
19 . The amorphous form of claim 17 having an X-ray powder diffraction pattern substantially as shown in FIG. 28 .
20 . A pharmaceutical composition comprising the solid form of claim 1 and a pharmaceutically acceptable carrier, diluent or excipient.
21 . A pharmaceutical composition comprising the amorphous form of claim 20 and a pharmaceutically acceptable carrier, diluent or excipient.
22 . The pharmaceutical composition of claim 21 , wherein the composition is formulated for parenteral or intravenous administration.
23 . The pharmaceutical composition of claim 22 , wherein the composition is formulated as a single unit dosage form.Join the waitlist — get patent alerts
Track US2023212137A1 — get alerts on status changes and closely related new filings.
We store only your email — no account needed. See our privacy policy.